Surviving The Microbiome Market with MaaT Pharma's Hervé Affagard
Business Of Biotech
00:00
The Value of Collaboration in Hematopoietic Stem Cell Transplants
We are exploring collaboration with academic centers to provide our products to normalize the microbiome before the patient gets the charty cell. And that's another avenue where we think there's a potential, so it's a good point. We are little bit like where we were with the HSTT, the Stenselle transplantation, a few years ago. But it's also starting on the chartycell field. When you see, I would say, the charty Cell, when they work, they work. It's very, very expensive. And it comes with a toxicity. So the fact that you couldn't move or guarantee the result of your procedure is super important. The potential
Transcript
Play full episode
